Development of a COVID-19 Vaccine

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93020C00052-P00002-9999-1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2023
  • Known Financial Commitments (USD)

    $2,717,614
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    STEVEN REED
  • Research Location

    United States of America
  • Lead Research Institution

    HDT BIO CORPORATION
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.